News

Arrevus announced that the U.S. Food and Drug Administration (FDA) has given a form of priority review to ARV-1801 (sodium fusidate tablets), a potential oral treatment of pulmonary exacerbations in people with cystic fibrosis (CF). A clinical trial in patients is in planning stages, the company added in a…

A triple-antibiotic combination completely eliminated antibiotic-resistant Mycobacterium abscessus, a bacterial infection especially dangerous to people with cystic fibrosis (CF), a study found.  Combined doses of three antibiotics — amoxicillin, imipenem, and relebactam — were effective at killing…

Cystic fibrosis (CF) patients with low body weight are not at increased risk of mortality after a lung transplant, compared to people with other lung diseases who require the transplant, a new study reports. The findings were described in the study “Underweight patients with cystic fibrosis…

A project aimed at personalized medicine based on the use of organoids, or “mini-organs,” from cystic fibrosis (CF) patients with rare mutations is on track to collect samples from 500 people with CF by the end of April, Proteostasis Therapeutics announced. The organoids will be used as a…

Crestone has received an award from the Cystic Fibrosis Foundation (CFF) to develop preclinical studies for an antibiotic to treat non-tuberculous mycobacteria (NTM) infections. NTMs are responsible for lung infections in 14% of people with cystic fibrosis (CF). The number of people affected by lung NTM infections is steadily…

Enrollment is nearing completion for two Phase 2 clinical trials testing the experimental treatment ELX-02 in people with cystic fibrosis (CF), according to Eloxx Pharmaceuticals, the company developing ELX-02. “We expect full enrollment to be achieved during the first quarter of 2020, and to report topline results…

The Cystic Fibrosis (CF) Foundation awarded a nearly $700,000 contract to Calibr, the drug discovery and development arm of Scripps Research, to support projects aiming to identify compounds that could treat infections caused by Burkholderia cepacia complex. The contract will provide funding for two years, and is valued…

Enterprise Therapeutics‘ experimental compound called ETX001 was able to increase airway fluid secretion and mucus clearance in preclinical models of cystic fibrosis (CF), a study reports. ETX001 is a potentiator of a chloride channel called TMEM16A. Because TMEM16A’s production and function are independent of CFTR — the protein that…

Cystic fibrosis (CF) advocate, author, Olympic torchbearer, and motivational speaker Andy Lipman didn’t get involved in the CF community — even though he himself had the disease — until a friend had him volunteer in a softball charity event.

Proteostasis Therapeutics announced plans to open two Phase 3 clinical trials of its triple combination therapy candidate for cystic fibrosis this year, after a meeting with the chief healthcare regulatory office for the U.K. One of these pivotal trials will be investigating the possibility of organoids being used for personalized…